Efficacy and risk of mRNA vaccination in patients with autoimmune inflammatory rheumatic diseases

Inflammation and Regeneration

Review

Yasuhiro Kato¹  Takayoshi Morita¹  Atsushi Kumanogoh² 

[1] Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan;Department of Immunopathology, Immunology Frontier Research Center (iFReC), Osaka University, Suita, Osaka, Japan;Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan;Department of Immunopathology, Immunology Frontier Research Center (iFReC), Osaka University, Suita, Osaka, Japan;Center for Infectious Diseases Education and Research (CiDER), Osaka University, Suita, Osaka, Japan;Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University, Suita, Osaka, Japan;Japan Agency for Medical Research and Development — Core Research for Evolutional Science and Technology (AMED–CREST), Osaka University, Osaka, Japan;Center for Advanced Modalities and DDS (CAMaD), Osaka University, Osaka, Japan;

关键词: COVID-19;    SARS-CoV-2;    Autoimmune inflammatory rheumatic disease (AIRD);    mRNA vaccine;    Immune response;   

DOI  :  10.1186/s41232-022-00247-1

 received in 2022-09-09, accepted in 2022-11-28,  发布年份 2022

来源: Springer

【 摘 要 】

Coronavirus disease 2019 (COVID-19), which spread worldwide from Wuhan, China, in 2019, appeared for a time to be overcome by the remarkable efficacy of mRNA vaccines; however, new variants of severe acute respiratory syndrome coronavirus 2 have emerged and remain rampant. The involvement of the virus in the emergence of variant strains and the relationship between vaccine efficacy and immunosuppressive drugs have attracted significant attention, particularly with regard to patients with autoimmune inflammatory rheumatic disease (AIRD) who take immunosuppressive drugs. This review outlines the relationship between mRNA vaccines, one of the key strategies against COVID-19, and AIRD and discusses the immune response elicited by mRNA vaccines. Furthermore, the impact of immunosuppressive agents on the mRNA vaccine-induced immune response in patients with AIRD and side effects of the vaccine, such as exacerbation of the underlying disease, is outlined.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

41116_2022_35_Article_IEq338.gif